Telomir Pharmaceuticals (TELO) Competitors $1.45 -0.05 (-3.33%) Closing price 04:00 PM EasternExtended Trading$1.46 +0.01 (+0.34%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. GNFT, CTMX, TIL, EDIT, SXTC, DERM, TVGN, ACRS, LFVN, and CCCCShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include GENFIT (GNFT), CytomX Therapeutics (CTMX), Instil Bio (TIL), Editas Medicine (EDIT), China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), Semper Paratus Acquisition (TVGN), Aclaris Therapeutics (ACRS), Lifevantage (LFVN), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors GENFIT CytomX Therapeutics Instil Bio Editas Medicine China SXT Pharmaceuticals Journey Medical Semper Paratus Acquisition Aclaris Therapeutics Lifevantage C4 Therapeutics Telomir Pharmaceuticals (NASDAQ:TELO) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Which has stronger earnings and valuation, TELO or GNFT? GENFIT has higher revenue and earnings than Telomir Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.69GENFIT$67.00M3.22$1.63MN/AN/A Which has more volatility and risk, TELO or GNFT? Telomir Pharmaceuticals has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Is TELO or GNFT more profitable? GENFIT's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -4,595.08% -1,750.91% GENFIT N/A N/A N/A Does the media refer more to TELO or GNFT? In the previous week, GENFIT had 9 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for GENFIT and 0 mentions for Telomir Pharmaceuticals. GENFIT's average media sentiment score of 1.00 beat Telomir Pharmaceuticals' score of 0.84 indicating that GENFIT is being referred to more favorably in the news media. Company Overall Sentiment Telomir Pharmaceuticals Positive GENFIT Positive Do analysts rate TELO or GNFT? Telomir Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 934.48%. GENFIT has a consensus price target of $9.00, indicating a potential upside of 108.53%. Given Telomir Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than GENFIT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50GENFIT 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in TELO or GNFT? 2.2% of GENFIT shares are held by institutional investors. 4.2% of GENFIT shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryGENFIT beats Telomir Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.81M$2.80B$5.82B$9.74BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-2.6922.6131.1525.97Price / SalesN/A751.86475.57123.18Price / CashN/A173.2237.1558.38Price / Book145.005.869.116.39Net Income-$16.53M$31.83M$3.26B$265.66M7 Day Performance-2.68%1.80%2.11%1.98%1 Month Performance-30.95%4.36%5.12%1.33%1 Year Performance-74.38%11.44%31.25%21.15% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.2027 of 5 stars$1.45-3.3%$15.00+934.5%-72.4%$46.81MN/A-2.691Gap DownGNFTGENFIT2.26 of 5 stars$3.79+1.6%$13.00+243.0%-3.5%$186.51M$76.77M0.00120News CoverageAnalyst ForecastAnalyst RevisionGap UpCTMXCytomX Therapeutics4.0795 of 5 stars$1.86-19.5%$5.75+209.1%+59.8%$186.24M$138.10M3.32170High Trading VolumeTILInstil Bio3.4358 of 5 stars$26.83-5.4%$119.00+343.5%+120.9%$185.95MN/A-2.24410EDITEditas Medicine4.2435 of 5 stars$2.29+4.1%$4.70+105.2%-33.1%$184.17M$35.84M-0.75230SXTCChina SXT Pharmaceuticals0.4527 of 5 stars$1.59+0.3%N/A-77.2%$183.90M$1.74M0.0090News CoverageShort Interest ↑Gap UpDERMJourney Medical1.6736 of 5 stars$8.54+8.5%$9.50+11.2%+60.9%$183.34M$56.13M-21.9090High Trading VolumeTVGNSemper Paratus Acquisition4.0152 of 5 stars$0.96-1.8%$10.00+939.0%+46.3%$180.22MN/A0.003Earnings ReportACRSAclaris Therapeutics2.7932 of 5 stars$1.64flat$8.71+431.4%+37.8%$177.66M$16.79M-1.20100LFVNLifevantage3.9835 of 5 stars$14.16+2.9%$30.50+115.4%+48.4%$173.21M$200.16M20.52260News CoverageUpcoming EarningsCCCCC4 Therapeutics1.2752 of 5 stars$2.24-7.4%$8.00+257.1%-58.6%$172.23M$35.58M-1.42150 Related Companies and Tools Related Companies GENFIT Alternatives CytomX Therapeutics Alternatives Instil Bio Alternatives Editas Medicine Alternatives China SXT Pharmaceuticals Alternatives Journey Medical Alternatives Semper Paratus Acquisition Alternatives Aclaris Therapeutics Alternatives Lifevantage Alternatives C4 Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access